Literature DB >> 15730889

Behavioral and cellular consequences of increasing serotonergic activity during brain development: a role in autism?

Patricia M Whitaker-Azmitia1.   

Abstract

The hypothesis explored in this review is that the high levels of serotonin in the blood seen in some autistic children (the so-called hyperserotonemia of autism) may lead to some of the behavioral and cellular changes also observed in the disorder. At early stages of development, when the blood-brain Barrier is not yet fully formed, the high levels of serotonin in the blood can enter the brain of a developing fetus and cause loss of serotonin terminals through a known negative feedback function of serotonin during development. The loss of serotonin innervation persists throughout subsequent development and the symptoms of autism appear. A review of the basic scientific literature on prenatal treatments affecting serotonin is given, in support of this hypothesis, with an emphasis on studies using the serotonin agonist, 5-methoxytryptamine (5-MT). In work using 5-MT to mimic hyperserotonemia, Sprague-Dawley rats are treated from gestational day 12 until postnatal 20. In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and "autistic-like" behaviors. In preliminary cellular findings given in this review, the animals have also been found to have cellular changes in two relevant brain regions: 1. Central nucleus of the amygdala, a brain region involved in fear-responding, where an increase in calcitonin gene related peptide (CGRP) was found 2. Paraventricular nucleus of the hypothalamus, a brain region involved in social memory and bonding, where a decrease in oxytocin was found. Both of these cellular changes could result from loss of serotonin innervation, possibly due to loss of terminal outgrowth from the same cells of the raphe nuclei. Thus, increased serotonergic activity during development could damage neurocircuitry involved in emotional responding to social stressors and may have relevance to the symptoms of autism.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15730889     DOI: 10.1016/j.ijdevneu.2004.07.022

Source DB:  PubMed          Journal:  Int J Dev Neurosci        ISSN: 0736-5748            Impact factor:   2.457


  82 in total

1.  Dose-dependent effects of neonatal SSRI exposure on adult behavior in the rat.

Authors:  Sharonda S Harris; Dorota Maciag; Kimberly L Simpson; Rick C S Lin; Ian A Paul
Journal:  Brain Res       Date:  2011-10-20       Impact factor: 3.252

Review 2.  Investigating outcomes following the use of selective serotonin reuptake inhibitors for treating depression in pregnancy: a focus on methodological issues.

Authors:  Luke E Grzeskowiak; Andrew L Gilbert; Janna L Morrison
Journal:  Drug Saf       Date:  2011-11-01       Impact factor: 5.606

3.  Developmental exposure to a serotonin agonist produces subsequent behavioral and neurochemical changes in the adult male prairie vole.

Authors:  Melissa M Martin; Yan Liu; Zuoxin Wang
Journal:  Physiol Behav       Date:  2011-09-17

4.  Density and function of central serotonin (5-HT) transporters, 5-HT1A and 5-HT2A receptors, and effects of their targeting on BTBR T+tf/J mouse social behavior.

Authors:  Georgianna G Gould; Julie G Hensler; Teresa F Burke; Robert H Benno; Emmanuel S Onaivi; Lynette C Daws
Journal:  J Neurochem       Date:  2010-12-02       Impact factor: 5.372

5.  Short- and long-term functional consequences of fluoxetine exposure during adolescence in male rats.

Authors:  Sergio D Iñiguez; Brandon L Warren; Carlos A Bolaños-Guzmán
Journal:  Biol Psychiatry       Date:  2010-02-20       Impact factor: 13.382

6.  Comparison of the maturation of the adrenergic and serotonergic neurotransmitter systems in the brain: implications for differential drug effects on juveniles and adults.

Authors:  L Charles Murrin; Jeff D Sanders; David B Bylund
Journal:  Biochem Pharmacol       Date:  2007-01-25       Impact factor: 5.858

7.  Evidence for epistasis between SLC6A4 and ITGB3 in autism etiology and in the determination of platelet serotonin levels.

Authors:  Ana M Coutinho; Inês Sousa; Madalena Martins; Catarina Correia; Teresa Morgadinho; Celeste Bento; Carla Marques; Assunção Ataíde; Teresa S Miguel; Jason H Moore; Guiomar Oliveira; Astrid M Vicente
Journal:  Hum Genet       Date:  2007-01-03       Impact factor: 4.132

Review 8.  Early pharmacological treatment of autism: a rationale for developmental treatment.

Authors:  Terrence C Bethea; Linmarie Sikich
Journal:  Biol Psychiatry       Date:  2007-02-15       Impact factor: 13.382

Review 9.  Developmental changes in serotonin signaling: Implications for early brain function, behavior and adaptation.

Authors:  S Brummelte; E Mc Glanaghy; A Bonnin; T F Oberlander
Journal:  Neuroscience       Date:  2016-02-22       Impact factor: 3.590

10.  Examining the Reversibility of Long-Term Behavioral Disruptions in Progeny of Maternal SSRI Exposure.

Authors:  Susan E Maloney; Shyam Akula; Michael A Rieger; Katherine B McCullough; Krystal Chandler; Adrian M Corbett; Audrey E McGowin; Joseph D Dougherty
Journal:  eNeuro       Date:  2018-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.